New Delhi: A compound found in the bark of magnolia tree inhibits reproduction of the SARS-CoV-2 virus, which causes COVID-19, in several types of cells, and may be effective against future coronaviruses, according to a study.
The researchers found that the compound called honokiol caused the production of infectious SARS-CoV-2 viral particles in treated cells to fall to around 1,000th of the previous level.
The research, published in the journal Microbiology Spectrum, also shows that the compound inhibited replication of other highly pathogenic human coronaviruses, including Middle East respiratory syndrome (MERS) and Severe acute respiratory syndrome (SARS).
“This suggests that it has a broad spectrum of activity and would likely also inhibit novel coronaviruses that might emerge in the future,” said Martijn J. van Hemert, Associate Professor at Leiden University in The Netherlands.
“If honokiol can be developed into a drug, possibly in combination with other compounds, stockpiling it would help us to increase our preparedness for the emergence of the next coronavirus,” said van Hemert.
Broad-spectrum drugs could then be used to treat early patients and prevent spread, or they could be used prophylactically among healthcare workers, and in high-risk groups, such as among nursing home residents, the researchers said.
Honokiol also has anti-inflammatory properties that could be helpful in cases where patients wait until a relatively late stage of the disease to obtain medical treatment, by which time the body’s own inflammatory responses to the infection are causing symptoms, van Hemert noted.
“At that point, inhibition of virus replication might no longer be helpful, but honokiol’s anti-inflammatory response might mitigate the illness,” van Hemert explained.
Honokiol inhibits a later step of the viral replication cycle — one that takes place after the virus has entered the cell.
The researchers suspect that honokiol does so by triggering processes in the host cell that impede replication of the virus. It did so in the case of the original SARS-CoV-2 variants, and also in that of the more recent Omicron variants.
Dear Reader,
Over the past four years, EastMojo revolutionised the coverage of Northeast India through our sharp, impactful, and unbiased overage. And we are not saying this: you, our readers, say so about us. Thanks to you, we have become Northeast India’s largest, independent, multimedia digital news platform.
Now, we need your help to sustain what you started.
We are fiercely protective of our ‘independent’ status and would like to remain so: it helps us provide quality journalism free from biases and agendas. From travelling to the remotest regions to cover various issues to paying local reporters honest wages to encourage them, we spend our money on where it matters.
Now, we seek your support in remaining truly independent, unbiased, and objective. We want to show the world that it is possible to cover issues that matter to the people without asking for corporate and/or government support. We can do it without them; we cannot do it without you.
Support independent journalism, subscribe to EastMojo.
Thank you,
Karma Paljor
Editor-in-Chief, eastmojo.com
“Our study merely provides the basis for further research into potential therapeutic applications,” said van Hemert.
“It is important to mention that it is too early to claim that honokiol might be used in SARS-CoV-2 patients. This requires much more research and — if successful — properly conducted clinical trials,” the researcher added.
Also Read | Active Covid cases in country dip to 6,591
Trending Stories
- Pakistan may pull out of Asia Cup after SL, Afghan, Bangladesh reject ‘Hybrid Model’
- Odisha train crash: Assam man recalls co-traveler’s severed head on chest
- Meghalaya Cabinet to amend memo on roster system
- Meghalaya on the verge of shutting Umiam dam: CM Conrad
- PM Modi has prioritised road development in border areas: Rijiju
- Bengal man finds his ‘dead’ son alive in Balasore makeshift morgue
